Non-formulary **lansoprazole oral disintegrating tablet** will be covered on the prescription drug benefit when the following criteria are met:

- Patient is not currently swallowing any other medications in capsule/tablet form (only approved for patients unable to swallow solid dosage forms)

  - **AND** -

  - Patient has failed an adequate trial of omeprazole 2 mg/mL oral suspension OR patient has an allergy or intolerance to omeprazole

  - **AND** -

  - Patient has failed an adequate trial of lansoprazole 3 mg/mL oral suspension OR patient has an allergy or intolerance to lansoprazole suspension

**Notes:**
- Adequate trial is defined as 14-day treatment duration
- Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation